Cytodyn
Biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses.
Launch date
Employees
Market cap
€166m
Enterprise valuation
€190m (Public information from Sep 2024)
Share price
$0.16 CYDY
Lake Oswego Oregon (HQ)
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | <1m | - | - |
| EBITDA | - | - | (73.4m) | (93.0m) | (80.2m) | (64.1m) | (30.5m) |
| % EBITDA margin | - | - | - | - | (30169 %) | - | - |
| Profit | - | - | (124m) | (155m) | (211m) | (79.8m) | (49.8m) |
| % profit margin | - | - | - | - | (79256 %) | - | - |
| EV / revenue | - | - | - | - | 989.5x | - | - |
| EV / EBITDA | - | - | -20.8x | -13.1x | -3.3x | -4.3x | -6.0x |
| R&D budget | - | - | 52.6m | 58.4m | 27.0m | 2.6m | 7.2m |
| R&D % of revenue | - | - | - | - | 10167 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $2.3m | Series A | |
| N/A | N/A | Seed | |
| N/A | $3.0m | Post IPO Equity | |
| N/A | N/A | Growth Equity VC | |
| N/A | $5.9m | Post IPO Equity | |
| N/A | $1.2m | Convertible | |
| N/A | $3.2m | Post IPO Equity | |
| N/A | $3.3m | Post IPO Debt | |
| N/A | $2.7m | Post IPO Equity | |
| N/A | $5.9m | Post IPO Equity | |
| N/A | $4.3m | Post IPO Equity | |
| N/A | $15.0m | Post IPO Debt | |
| Total Funding | €3.2m | ||
Related Content
Recent News about Cytodyn
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.